12.50
+0.02(+0.16%)
Currency In USD
Address
4850 West 78th Street
Indianapolis, IN 46268
United States of America
Phone
647 812 2417
Sector
Healthcare
Industry
Biotechnology
Employees
129
First IPO Date
July 08, 2020
| Name | Title | Pay | Year Born |
| Dr. Joe A. McCann Ph.D. | Chief Executive Officer & Director | 1.06M | 1978 |
| Dr. Neil E. Fleshner FRCSC, M.D., M.PH | Chief Medical Officer & Director | 318,485 | 1964 |
| Ms. Jessica D. Jensen M.P.H., MPH | Executive Vice President of Clinical Devel. | 816,171 | 1981 |
| Mr. Allan Charles Silber | Executive Chairman | 1.02M | 1950 |
| Mr. Todd Hockemeyer B.E. | Executive Vice President of US Manufacturing Operations | 0 | N/A |
| Ms. Donna Husack B.A. | Vice President of HR | 0 | N/A |
| Mr. Chris Horvath | Executive Vice President of Commercial | 0 | N/A |
| Ms. Melita Ann Sequeira B.Sc. | Senior Vice President of People & Culture | 0 | N/A |
| Ms. Jazz Braich | SVice President of People & Culture | 0 | N/A |
| Ms. Justyna Kelly M.Sc. | Chief Operating Officer | 0 | 1985 |
| Dr. Myra Rosario Herle Ph.D., R.Ph. | Executive Vice President of Regulatory Affairs | 0 | N/A |
POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of non-metastatic castration sensitive prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-a targeting program being developed for use in multiple tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana.